Jinge Zhao
Overview
Explore the profile of Jinge Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhao J, Cai D, Chen Y, Dai J, Tu X, Chen J, et al.
Int J Surg
. 2024 Oct;
111(1):1636-1641.
PMID: 39453842
No abstract available.
12.
He S, Liu H, Hu X, Zhao J, Liang J, Zhang X, et al.
BMC Infect Dis
. 2024 Sep;
24(1):1000.
PMID: 39294577
Background: A new pathogen detection tool, metagenomic next-generation sequencing (mNGS), has been widely used for infection diagnosis, but the clinical and diagnostic value of mNGS in urinary tract infection (UTI)...
13.
Zeng H, Chen Y, Zhao J, Dai J, Xie Y, Wang M, et al.
World J Urol
. 2024 Aug;
42(1):495.
PMID: 39177844
Objectives: To develop and validate a prediction model for identifying non-prostate cancer (non-PCa) in biopsy-naive patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml to avoid unnecessary...
14.
Wang X, Zhao J, Zhang J, Cao J, Yu Y, Ma B, et al.
Anal Chem
. 2024 Jul;
96(32):13317-13325.
PMID: 39080839
The construction of coassembled peptide nanoprobes based on structural adaptation provides an effective template for stable monitoring of the molecular events in physiological and pathological processes. This also greatly expands...
15.
Zhao J, Pan X, Wang Z, Chen Y, Liu D, Shen Y, et al.
Eur J Med Res
. 2024 Jul;
29(1):378.
PMID: 39033192
Background: A substantial proportion of patients with metastatic clear cell renal cell carcinoma (ccRCC) cannot derive benefit from immune checkpoint inhibitor (ICI) plus anti-angiogenic agent combination therapy, making identification of...
16.
Wang Z, Liu H, Zhu Q, Chen J, Zhao J, Zeng H
BMC Cancer
. 2024 Jul;
24(1):817.
PMID: 38978000
Background: Inflammation plays a pivotal role in the progression of prostate cancer (PCa). Several immune-inflammatory indices, including neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), lymphocyte to...
17.
Zhao J, Tang Y, Hu X, Yin X, Chen Y, Chen J, et al.
Mol Cancer
. 2024 Jun;
23(1):132.
PMID: 38926757
Background: TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to...
18.
Zhao J, Zhang L, Cao J, Yu Y, Ma B, Jiang Y, et al.
Anal Chem
. 2024 Jun;
96(27):11092-11102.
PMID: 38924493
Peptide self-assemblies could leverage their specificity, stability, biocompatibility, and electrochemical activity to create functionalized interfaces for molecular sensing and detection. However, the dynamics within these interfaces are complex, with competing...
19.
Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, et al.
Cancer Treat Rev
. 2024 Jun;
129:102787.
PMID: 38905806
Background: This study aimed to summarize the occurrence of immune-related adverse events (irAEs) and further evaluate their association with clinical outcomes in patients with advanced renal cell carcinoma (RCC) and...
20.
Zhu Q, Chen J, Liu H, Zhao J, Xu C, Sun G, et al.
BMC Cancer
. 2024 Jun;
24(1):706.
PMID: 38851712
Background: Poly (ADP- ribose) polymerase inhibitors (PARPi) has been increasingly adopted for metastatic castration-resistance prostate cancer (mCRPC) patients with homologous recombination repair deficiency (HRD). However, it is unclear which PARPi...